MY183186A - Phenyl derivative - Google Patents
Phenyl derivativeInfo
- Publication number
- MY183186A MY183186A MYPI2015703351A MYPI2015703351A MY183186A MY 183186 A MY183186 A MY 183186A MY PI2015703351 A MYPI2015703351 A MY PI2015703351A MY PI2015703351 A MYPI2015703351 A MY PI2015703351A MY 183186 A MY183186 A MY 183186A
- Authority
- MY
- Malaysia
- Prior art keywords
- disease
- compound
- fibrosis
- antagonistic activity
- strong human
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 101000693262 Homo sapiens Sphingosine 1-phosphate receptor 2 Proteins 0.000 abstract 2
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 abstract 2
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 102000054996 human S1PR2 Human genes 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013063304 | 2013-03-26 | ||
| PCT/JP2014/058211 WO2014157158A1 (ja) | 2013-03-26 | 2014-03-25 | フェニル誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY183186A true MY183186A (en) | 2021-02-18 |
Family
ID=51624129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015703351A MY183186A (en) | 2013-03-26 | 2014-03-25 | Phenyl derivative |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9676719B2 (enExample) |
| EP (1) | EP2980072B1 (enExample) |
| JP (1) | JP6245255B2 (enExample) |
| KR (1) | KR20150135281A (enExample) |
| CN (1) | CN105189454B (enExample) |
| AU (1) | AU2014245879B2 (enExample) |
| BR (1) | BR112015024897A2 (enExample) |
| CA (1) | CA2907964A1 (enExample) |
| DK (1) | DK2980072T3 (enExample) |
| ES (1) | ES2671559T3 (enExample) |
| HU (1) | HUE038919T2 (enExample) |
| MX (1) | MX2015013618A (enExample) |
| MY (1) | MY183186A (enExample) |
| NO (1) | NO2980072T3 (enExample) |
| NZ (1) | NZ712540A (enExample) |
| PH (1) | PH12015502203B1 (enExample) |
| PL (1) | PL2980072T3 (enExample) |
| PT (1) | PT2980072T (enExample) |
| RU (1) | RU2639875C2 (enExample) |
| SG (1) | SG11201507983XA (enExample) |
| TR (1) | TR201808812T4 (enExample) |
| WO (1) | WO2014157158A1 (enExample) |
| ZA (1) | ZA201507112B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013047701A1 (ja) * | 2011-09-29 | 2013-04-04 | 小野薬品工業株式会社 | フェニル誘導体 |
| KR102243426B1 (ko) * | 2013-03-26 | 2021-04-21 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐 유도체를 함유하는 의약 |
| EP3706728A1 (en) | 2017-11-08 | 2020-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | S1pr2 antagonists for treating diseases involving abnormal immune responses |
| WO2021026479A1 (en) * | 2019-08-07 | 2021-02-11 | Stamford, Andrew | Small molecule inhibitors of s1p2 receptor and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06234797A (ja) | 1993-02-10 | 1994-08-23 | Tsumura & Co | レセプター活性を有する新規ペプチドおよび該ペプチドをコードするｄｎａ |
| AU2001264313A1 (en) | 2000-06-20 | 2002-01-02 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| AU2003248245A1 (en) | 2002-06-26 | 2004-01-19 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
| CN1590378A (zh) | 2003-08-29 | 2005-03-09 | 中国科学院上海药物研究所 | 一类喹喔啉衍生物及其制备方法和用途 |
| WO2005020882A2 (ja) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co | Ｓ１ｐ受容体結合能を有する化合物およびその医薬用途 |
| RU2390519C2 (ru) | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
| US7825109B2 (en) * | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| JP4792974B2 (ja) | 2003-12-25 | 2011-10-12 | 小野薬品工業株式会社 | アゼチジン環化合物およびその医薬 |
| CA2650567A1 (en) | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Use of cbx cannabinoid receptor modulators as potassium channel modulators |
| JP2010514693A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| JP2012527435A (ja) | 2009-05-18 | 2012-11-08 | オリオン コーポレーション | プロテアーゼ阻害剤 |
| BR112012015721A2 (pt) | 2009-12-30 | 2017-09-26 | Avila Therapeutics Inc | modificação covalente de proteínas dirigida por ligante |
| JPWO2011087051A1 (ja) * | 2010-01-14 | 2013-05-20 | 国立大学法人金沢大学 | Ｓ１ｐ２受容体アンタゴニストを含む粥状動脈硬化治療薬 |
| WO2013047701A1 (ja) | 2011-09-29 | 2013-04-04 | 小野薬品工業株式会社 | フェニル誘導体 |
-
2014
- 2014-03-25 EP EP14775353.7A patent/EP2980072B1/en active Active
- 2014-03-25 BR BR112015024897A patent/BR112015024897A2/pt not_active Application Discontinuation
- 2014-03-25 ES ES14775353.7T patent/ES2671559T3/es active Active
- 2014-03-25 RU RU2015145460A patent/RU2639875C2/ru not_active IP Right Cessation
- 2014-03-25 CN CN201480017929.3A patent/CN105189454B/zh not_active Expired - Fee Related
- 2014-03-25 WO PCT/JP2014/058211 patent/WO2014157158A1/ja not_active Ceased
- 2014-03-25 TR TR2018/08812T patent/TR201808812T4/tr unknown
- 2014-03-25 PT PT147753537T patent/PT2980072T/pt unknown
- 2014-03-25 AU AU2014245879A patent/AU2014245879B2/en not_active Ceased
- 2014-03-25 PL PL14775353T patent/PL2980072T3/pl unknown
- 2014-03-25 HU HUE14775353A patent/HUE038919T2/hu unknown
- 2014-03-25 MY MYPI2015703351A patent/MY183186A/en unknown
- 2014-03-25 JP JP2015508522A patent/JP6245255B2/ja not_active Expired - Fee Related
- 2014-03-25 KR KR1020157025945A patent/KR20150135281A/ko not_active Withdrawn
- 2014-03-25 CA CA2907964A patent/CA2907964A1/en not_active Abandoned
- 2014-03-25 NZ NZ712540A patent/NZ712540A/en not_active IP Right Cessation
- 2014-03-25 US US14/780,152 patent/US9676719B2/en not_active Expired - Fee Related
- 2014-03-25 MX MX2015013618A patent/MX2015013618A/es unknown
- 2014-03-25 NO NO14775353A patent/NO2980072T3/no unknown
- 2014-03-25 SG SG11201507983XA patent/SG11201507983XA/en unknown
- 2014-03-25 DK DK14775353.7T patent/DK2980072T3/en active
-
2015
- 2015-09-21 PH PH12015502203A patent/PH12015502203B1/en unknown
- 2015-09-25 ZA ZA2015/07112A patent/ZA201507112B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE038919T2 (hu) | 2018-12-28 |
| RU2015145460A (ru) | 2017-05-02 |
| EP2980072A1 (en) | 2016-02-03 |
| SG11201507983XA (en) | 2015-10-29 |
| PT2980072T (pt) | 2018-06-06 |
| CA2907964A1 (en) | 2014-10-02 |
| US9676719B2 (en) | 2017-06-13 |
| HK1214588A1 (en) | 2016-07-29 |
| MX2015013618A (es) | 2016-02-25 |
| PH12015502203A1 (en) | 2016-02-01 |
| PL2980072T3 (pl) | 2018-08-31 |
| RU2639875C2 (ru) | 2017-12-25 |
| WO2014157158A1 (ja) | 2014-10-02 |
| ZA201507112B (en) | 2018-05-30 |
| DK2980072T3 (en) | 2018-06-14 |
| ES2671559T3 (es) | 2018-06-07 |
| TR201808812T4 (tr) | 2018-07-23 |
| JPWO2014157158A1 (ja) | 2017-02-16 |
| PH12015502203B1 (en) | 2016-02-01 |
| CN105189454B (zh) | 2018-07-13 |
| AU2014245879A1 (en) | 2015-10-15 |
| AU2014245879B2 (en) | 2017-12-21 |
| CN105189454A (zh) | 2015-12-23 |
| EP2980072B1 (en) | 2018-04-25 |
| EP2980072A4 (en) | 2016-11-23 |
| NZ712540A (en) | 2018-06-29 |
| NO2980072T3 (enExample) | 2018-09-22 |
| US20160039757A1 (en) | 2016-02-11 |
| KR20150135281A (ko) | 2015-12-02 |
| JP6245255B2 (ja) | 2017-12-13 |
| BR112015024897A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502363A1 (en) | Brk inhibitory compound | |
| NZ711424A (en) | Pyridine derivatives as soft rock inhibitors | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| MX363456B (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX356342B (es) | Agente de control de endoparásitos y método para usarlo. | |
| MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| MX373307B (es) | Compuestos de biaril-amida como inhibidores de cinasa. | |
| PH12015501363B1 (en) | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | |
| MD20150075A2 (ro) | Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale | |
| GEP201706621B (en) | Benzamides | |
| GEP201606598B (en) | Heteroaromatic compounds as dopamine d1 ligands | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| MX2020011818A (es) | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. | |
| IN2015DN03998A (enExample) | ||
| PH12014500561A1 (en) | Phenyl derivative | |
| NZ702346A (en) | Carbamate/urea derivatives | |
| GEP201606566B (en) | Isoxazolidine derivatives | |
| PH12015502203B1 (en) | Phenyl derivative | |
| PH12016500577B1 (en) | Piperazine derivatives and the use thereof as medicament | |
| MY197518A (en) | Preventive and/or therapeutic agent of immune disease | |
| TN2015000524A1 (en) | Pharmaceutical compositions | |
| PL401994A1 (pl) | Zastosowanie medyczne pochodnych 1-podstawionego 4-benzoilotiosemikarbazydu | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives | |
| WO2013175347A3 (en) | Compositions and methods for treatment of respiratory disorders |